Biogen (BIIB) Investment Income (2019 - 2022)

Biogen has reported Investment Income for 4 years, with the latest figure at $5.9 million in Q2 2022.

• On a quarterly basis, Investment Income fell 82.8% year-over-year to $5.9 million in Q2 2022; TTM through Mar 2023 was $5.9 million, a 88.15% decrease from a year earlier, with the FY2022 full-year figure at $2.6 million, down 92.55% from the prior year.
• Investment Income was $5.9 million for Q2 2022 at Biogen, up from -$3.3 million in the prior quarter.
• The five-year high for Investment Income was $34.3 million in Q2 2021, with the low at -$21.8 million in Q3 2019.
• Average Investment Income over 4 years is $691666.7, with a median of -$1.1 million recorded in 2021.
• The sharpest annual moves came in 2020 and 2022: Investment Income surged 242.86% in 2020, then sank 82.8% in 2022.
• Over 4 years, Investment Income stood at -$12.6 million in 2019, then soared by 242.86% to $18.0 million in 2020, then decreased by 1.67% to $17.7 million in 2021, then slumped by 66.67% to $5.9 million in 2022.
• The last three Investment Income figures came in at $5.9 million (Q2 2022), -$3.3 million (Q1 2022), and $17.7 million (Q4 2021), per Business Quant data.